Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas
Status:
NOT_YET_RECRUITING
Trial end date:
2031-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label, dose-finding study of XRD-0394 in subjects with newly diagnosed and recurrent high grade gliomas receiving radiation therapy, with and without concurrent temozolomide based on O6-Methylguanine-DNA methyltransferase (MGMT) status for patients with newly diagnosed high grade gliomas.